AZ 07
Alternative Names: AZ-07Latest Information Update: 22 Mar 2023
At a glance
- Originator Azurity Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown CNS disorders
Most Recent Events
- 22 Mar 2023 Clinical trials in CNS disorders in USA (unspecified route) (Azurity Pharmaceuticals pipeline, March 2023)
- 06 Apr 2022 AZ 07 is available for licensing as of 06 Apr 2022. https://azurity.com/pipeline/ (Azurity Pharmaceuticals website, April 2022)
- 06 Apr 2022 Early research in CNS disorders in USA (unspecified route) (Azurity Pharmaceuticals pipeline, April 2022)